Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedSep 23, 2015Testosterone Cypionate 250 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1755-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 50 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1754-2015Class IITerminatedSep 23, 2015Testosterone Bi-Blend 50 mg/ml + Estradiol Valerate 2.5 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1753-2015Class IITerminatedSep 23, 2015Testosterone Bi-Blend 15 mg/ml +Estradiol Valerate 5 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1752-2015Class IITerminatedSep 23, 2015Testosterone 87.5 mg Sterile PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1751-2015Class IITerminatedSep 23, 2015Testosterone 70 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1750-2015Class IITerminatedSep 23, 2015Testosterone 60 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1749-2015Class IITerminatedSep 23, 2015Testosterone 37.5 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1748-2015Class IITerminatedSep 23, 2015Testosterone 30 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1747-2015Class IITerminatedSep 23, 2015Testosterone 25 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1746-2015Class IITerminatedSep 23, 2015Testosterone 200 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1745-2015Class IITerminatedSep 23, 2015Testosterone 20 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1744-2015Class IITerminatedSep 23, 2015Testosterone 12.5 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1743-2015Class IITerminatedSep 23, 2015Testosterone 100 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1742-2015Class IITerminatedSep 23, 2015Testosterone 18 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1741-2015Class IITerminatedSep 23, 2015PGE 2 (Alprostadil) 100 mcg/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1740-2015Class IITerminatedSep 23, 2015MYO-DENLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1739-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 16 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1738-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 8 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1737-2015Class IITerminatedSep 23, 2015Morphine 30 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1736-2015Class IITerminatedSep 23, 2015MEGA-BURNLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1735-2015Class IITerminatedSep 23, 2015LIPOLEAN + Ascorbic Acid 50 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1734-2015Class IITerminatedSep 23, 2015LIPOLEAN InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1733-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Fentanyl 15Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1732-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Fentanyl 15Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1731-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1730-2015Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml+Fentanyl 16Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1729-2015Class IITerminatedSep 23, 2015Fentanyl 5Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1728-2015Class IITerminatedSep 23, 2015Betamethasone Sodium PhosphateLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1727-2015Class IITerminatedSep 23, 2015B-Complex 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1726-2015Class IITerminatedSep 23, 2015Baclofen 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1725-2015Class IITerminatedSep 23, 2015Vitatrim Active InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1724-2015Class IITerminatedSep 23, 2015Vitatrim InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1723-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1722-2015Class IITerminatedSep 23, 2015Tri-Mix InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1721-2015Class IITerminatedSep 23, 2015Tri-Mix Super InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1720-2015Class IITerminatedSep 23, 2015TRI-MIXLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1719-2015Class IITerminatedSep 23, 2015Quad-Mix 4 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1718-2015Class IITerminatedSep 23, 2015Quad-Mix 2 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1717-2015Class IITerminatedSep 23, 2015Quad-Mix 1 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1716-2015

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.